{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003286","form_type":"8-K","ticker":"TRVI","cik":"0001563880","company_name":"Trevi Therapeutics, Inc.","filed_at":"2025-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.002263+00:00","generated_at":"2026-05-28T06:40:52.063088+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Trevi Therapeutics reports $107.6M cash; Phase 2a RIVER completed enrollment; CORAL 80% enrolled","bullets":["Cash, cash equivalents, and marketable securities estimated at $107.6M as of Dec 31, 2024; runway into H2 2026.","Last patient completed final visit in Phase 2a RIVER trial (RCC); topline results expected Q1 2025.","Phase 2b CORAL trial (IPF chronic cough) now ~80% enrolled after positive SSRE; topline expected H1 2025.","SSRE analysis in Dec 2024 reaffirmed original sample size of N=160 for CORAL trial."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003286","json":"https://secwatch.observer/filing/0000950170-25-003286.json","markdown":"https://secwatch.observer/filing/0000950170-25-003286.md","text":"https://secwatch.observer/filing/0000950170-25-003286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025003286/0000950170-25-003286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563880/000095017025003286/trvi-20250108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T06:40:52.063088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}